Daniele Vergara , Pasquale Simeone , Julien Franck , Marco Trerotola , Anna Giudetti , Loredana Capobianco , Andrea Tinelli , Claudia Bellomo , Isabelle Fournier , Antonio Gaballo , Saverio Alberti , Michel Salzet , Michele Maffia
{"title":"Translating epithelial mesenchymal transition markers into the clinic: Novel insights from proteomics","authors":"Daniele Vergara , Pasquale Simeone , Julien Franck , Marco Trerotola , Anna Giudetti , Loredana Capobianco , Andrea Tinelli , Claudia Bellomo , Isabelle Fournier , Antonio Gaballo , Saverio Alberti , Michel Salzet , Michele Maffia","doi":"10.1016/j.euprot.2016.01.003","DOIUrl":null,"url":null,"abstract":"<div><p>The growing understanding of the molecular mechanisms underlying epithelial-to-mesenchymal transition (EMT) may represent a potential source of clinical markers. Despite EMT drivers have not yet emerged as candidate markers in the clinical setting, their association with established clinical markers may improve their specificity and sensitivity. Mass spectrometry-based platforms allow analyzing multiple samples for the expression of EMT candidate markers, and may help to diagnose diseases or monitor treatment efficiently. This review highlights proteomic approaches applied to elucidate the differences between epithelial and mesenchymal tumors and describes how these can be used for target discovery and validation.</p></div>","PeriodicalId":38260,"journal":{"name":"EuPA Open Proteomics","volume":"10 ","pages":"Pages 31-41"},"PeriodicalIF":0.0000,"publicationDate":"2016-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.euprot.2016.01.003","citationCount":"45","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EuPA Open Proteomics","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2212968516300034","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 45
Abstract
The growing understanding of the molecular mechanisms underlying epithelial-to-mesenchymal transition (EMT) may represent a potential source of clinical markers. Despite EMT drivers have not yet emerged as candidate markers in the clinical setting, their association with established clinical markers may improve their specificity and sensitivity. Mass spectrometry-based platforms allow analyzing multiple samples for the expression of EMT candidate markers, and may help to diagnose diseases or monitor treatment efficiently. This review highlights proteomic approaches applied to elucidate the differences between epithelial and mesenchymal tumors and describes how these can be used for target discovery and validation.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
